Correspondence
Osteonecrosis of the Jaw and Bisphosphonates
N Engl J Med 2005; 353:99-102July 7, 2005
- Article
To the Editor:
Cases of osteonecrosis of the jaw in connection with the use of bisphosphonates were reported in 2003.1,2 In 2004, the International Myeloma Foundation conducted a Web-based survey to assess the risk factors for osteonecrosis of the jaw. Of 1203 respondents, 904 had myeloma and 299 breast cancer. Both osteonecrosis and suspicious findings, including bone erosions and spurs plus exposed bone, were assessed. Sixty-two patients with myeloma had osteonecrosis of the jaw and 54 had suspicious findings; 13 patients with breast cancer had osteonecrosis and 23 had suspicious findings — a total of 152 patients with either osteonecrosis or suspicious findings. Of the patients with myeloma, 71 percent had received zoledronic acid and 29 percent had received only pamidronate.
Figure 1Figure 1
Time to the Onset of Osteonecrosis of the Jaw in Patients with Myeloma Receiving Zoledronic Acid or Pamidronate. displays the cumulative incidence of osteonecrosis of the jaw among patients receiving either zoledronic acid alone or pamidronate alone who responded to the survey. With censoring at 36 months, osteonecrosis of the jaw developed in 10 percent of 211 patients receiving zoledronic acid, as compared with 4 percent of 413 patients receiving pamidronate (P=0.002 by the log-rank test). The earlier onset of osteonecrosis of the jaw among patients receiving zoledronic acid during the first 36 months reflects remarkably well the reported increase in the occurrence of osteonecrosis in the first 36 months after the Food and Drug Administration approved the drug in 2001.The censored 36-month estimates of osteonecrosis, suspicious findings, or both did not differ between patients with myeloma and those with breast cancer (P>0.50). No other therapies, including corticosteroids and thalidomide, conferred an added risk over time (P>0.50). However, a history of underlying dental problems, such as infection or dental extraction, was present in 81 percent of patients with myeloma and in 69 percent of patients with breast cancer who had osteonecrosis of the jaw, as compared with 33 percent of those without osteonecrosis (P<0.001 and P=0.01, respectively, in a two-sided test). Maxillofacial surgery was a particular problem for patients with osteonecrosis of the jaw, since the surgery resulted in areas of nonhealing bone and soft tissue that were larger than those in patients who did not undergo surgery.
In September 2004, Novartis, the manufacturer of pamidronate (Aredia) and zoledronic acid (Zometa), issued post-marketing guidelines3 for both drugs in relation to osteonecrosis of the jaw that emphasized a particular risk with surgical intervention. The International Myeloma Foundation is working collaboratively with Novartis to raise awareness and develop enhanced guidelines. The full results of the study were presented to the Food and Drug Administration at an Oncology Drug Advisory Committee meeting held on March 4, 2005.4
4 ReferencesBrian G.M. Durie, M.D.
Cedars–Sinai Outpatient Cancer Center, Los Angeles, CA 90048-1804
bdurie@salick.com Michael Katz, M.B.A.
International Myeloma Foundation, North Hollywood, CA 91607-3421John Crowley, Ph.D.
Cancer Research and Biostatistics, Seattle, WA 98101-14681
Marx RE . Pamidronate (Aredia) and zoledronic acid (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117
CrossRef | Web of Science | Medline2
Ruggiero SL ,Mehrotra B ,Rosenberg TJ ,Engroff SL . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534
CrossRef | Web of Science | Medline3
Changes to the precautions and post-marketing experience sections of Aredia (pamidronate disodium) injection and Zometa (zoledronic acid) injection prescribing information related to osteonecrosis of the jaw. September 24, 2004 (package inserts). (Accessed June 16, 2005, at http://www.novartis.com.)
4
ODAC meeting transcripts. (Accessed June 16, 2005, at http://odac.myeloma.org.)
To the Editor:
Bisphosphonates are powerful osteoclast inhibitors with antitumor and antiangiogenic properties and a half-life of many years. The use of these drugs significantly reduces skeletal-related events in patients with multiple myeloma and other cancers.1 However, long-term use can result in suppression of bone turnover and compromised healing of even physiologic microinjuries within bone that occur as a result of day-to-day stresses.2
Osteonecrosis of the jaw has been reported recently in patients with cancer who were receiving either pamidronate or zolendronate, or both, and in those receiving alendronate for osteoporosis.3 Osteonecrosis of the jaw presents as an exposure of the mandible or maxilla that can be either painless or painful. Unlike osteoradionecrosis, osteonecrosis involves the maxilla fairly frequently, and as many as one fifth of cases occur spontaneously. We have seen more than 20 cases of osteonecrosis of the jaw in patients with myeloma at our institution during the past six months, although we had seen very few in previous years; the reasons for this increased incidence are unclear.
Osteonecrosis of the jaw probably results from the inability of hypodynamic and hypovascular bone to meet an increased demand for repair and remodeling owing to physiologic stress (mastication), iatrogenic trauma (tooth extraction or denture injury), or tooth infection in an environment that is trauma-intense and bacteria-laden. Coexisting factors may include the use of other medications with antiangiogenic properties (such as glucocorticoids, thalidomide, and bortezomib in patients with myeloma), diabetes mellitus, irradiation of the jawbone, peripheral vascular disease, and hyperviscosity syndromes. It is hypothesized that benign sequestration of the lingual mandibular plate in healthy persons results from physiologic trauma to the mucosa, leading to hypovascularity and focal bone death.4 Interestingly, this site is frequently involved in osteonecrosis.
Radical resection appears to be of limited use in cases of osteonecrosis of the jaw and may be contraindicated; the disease may progress despite surgery and cessation of bisphosphonate therapy.3 Factors such as underlying disease status, prognosis, extent of the lesion, presence or absence of jaw pain, and presence or absence of infection (not just surface bacterial colonization) should be considered when planning further treatment. Once bone resorption has been curtailed, there may be little benefit in giving lower doses of bisphosphonates, especially in patients receiving long-term bisphosphonate therapy.5
In our view, until studies in animals and prospective clinical trials shed more light on this condition, patients should be informed of the risk of osteonecrosis. Dentists and oral surgeons should judiciously remove all dental infections before or within a few weeks of the initiation of bisphosphonate therapy in this high-risk population of patients with cancer. Moreover, among patients receiving bisphosphonates in whom dental infections develop, withdrawal of the drugs until the infection is controlled may be warranted.
5 ReferencesSook-Bin Woo, D.M.D.
Brigham and Women's Hospital, Boston, MA 02115Karen Hande, N.P.
Paul G. Richardson, M.D.
Dana–Farber Cancer Institute, Boston, MA 021151
Berenson JR ,Rosen LS ,Howell A , et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-1200
CrossRef | Web of Science | Medline2
Odvina CV ,Zerwekh JE ,Rao DS ,Maalouf N ,Gottschalk FA ,Pak CYC . Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-1301
CrossRef | Web of Science | Medline3
Ruggiero SL ,Mehrotra B ,Rosenberg TJ ,Engroff SL . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534
CrossRef | Web of Science | Medline4
Peters E ,Lovas GL ,Wysocki GP . Lingual mandibular sequestration and ulceration. Oral Surg Oral Med Oral Pathol 1993;75:739-743
CrossRef | Medline5
Ott SM . Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005;90:1897-1899
CrossRef | Web of Science | Medline
To the Editor:
The main known risk factors for osteonecrosis of the jaw are dental procedures, poor dental hygiene, corticosteroid therapy, and local radiotherapy. More recently, treatment with bisphosphonates, such as pamidronate and zoledronic acid, was reported to be associated with osteonecrosis of the jaw among cancer patients.1,2 However, other confounding risk factors for osteonecrosis were also noted in published reports, especially dental procedures during therapy.3 As a consequence, the manufacturer of zoledronic acid recently modified its U.S. post-marketing and precautions information with the following statement regarding dental care: “While on treatment, these patients should avoid invasive dental procedures, if possible” (www.pharma.us.novartis.com).
We report nine cases of well-documented osteonecrosis of the jaw that occurred in patients who were receiving therapy with zoledronic acid but had not undergone dental procedures. In September 2002, we started using zoledronic acid almost exclusively for skeletal protection in patients with cancer. Zoledronic acid was given every three or four weeks at a dose of 4 mg intravenously during a period of 15 minutes. Between December 2003 and July 2004, nine cases of osteonecrosis of the jaw were diagnosed at our institution (four in patients with multiple myeloma and five in patients with metastatic breast cancer) among 194 patients treated with zoledronic acid. Before receiving zoledronic acid, six patients had been treated first with pamidronate (90 mg every three or four weeks). Eight of the nine patients had biopsy-proven osteonecrosis of the jaw. All the cases were diagnosed while the patients were receiving zoledronic acid. The median duration of treatment with pamidronate was 39 months (range, 4 to 58), with a median cumulative dose of 3060 mg (range, 360 to 5520). For zoledronic acid, the median duration of therapy before the appearance of osteonecrosis was 18 months (range, 4 to 22), and the median cumulative dose was 72 mg (range, 36 to 88).
The percentage of cases of osteonecrosis of the jaw that are associated with zoledronic acid is high in our institution (4.6 percent). Nevertheless, our data confirm other previous reports concerning the possible association between bisphosphonates and osteonecrosis of the jaw. From our observations, it is unclear which bisphosphonate, zoledronic acid or pamidronate, is the causal agent. However, our analysis provides more evidence that further investigations should be performed to determine which patients are at increased risk for osteonecrosis of the jaw, what is the optimal and safe duration of treatment, and what recommendations should be made for the follow-up of patients being treated with bisphosphonates.
3 ReferencesMarie Maerevoet, M.D.
Charlotte Martin, M.D.
Lionel Duck, M.D.
Clinique St.-Pierre, 1340 Ottignies, Belgium
li.duck@clinique-saint-pierre. be 1
Ruggiero SL ,Mehrotra B ,Rosenberg TJ ,Engroff SL . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534
CrossRef | Web of Science | Medline2
Marx RE . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117
CrossRef | Web of Science | Medline3
Tarassoff P ,Csermak K . Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003;61:1238-1239
CrossRef | Web of Science | Medline
Author/Editor Response
The letters published in this issue of the Journal, as well as case reports published since 2003,1-3 underscore the fact that osteonecrosis of the jaw is a concern for cancer patients and their physicians. As the developer of Aredia (pamidronate) and Zometa (zoledronic acid), we have obtained expert advice on how to revise the labels for these two drugs. Our labeling recommends a dental examination to identify and correct predisposing conditions before bisphosphonate treatment is started in patients with potential risk factors, including cancer.4 This approach may help identify and rectify dental problems before or during treatment so that osteonecrosis of the jaw may be prevented or its progression limited. Patients taking bisphosphonates should avoid invasive dental procedures, if possible. Further, more conservative treatments for osteonecrosis of the jaw may also include systemic antibiotics to control or prevent infection, as well as antimicrobial oral rinses.
Dental surgery may exacerbate osteonecrosis of the jaw in patients in whom the condition has developed during bisphosphonate therapy. No data are available to suggest whether discontinuation of bisphosphonate treatment in patients requiring dental procedures reduces the risk of osteonecrosis. Collaboration between the oncology and dental communities will be important for gaining better insights into the optimal treatment of patients with osteonecrosis of the jaw.
4 ReferencesPeter Tarassoff, M.D., Ph.D.
Yong-jiang Hei, M.D., Ph.D.
Novartis Pharmaceuticals, East Hanover, NJ 079361
Marx RE . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117
CrossRef | Web of Science | Medline2
Ruggiero SL ,Mehrotra B ,Rosenberg TJ ,Engroff SL . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534
CrossRef | Web of Science | Medline3
Bagan JV ,Murillo J ,Jimenez Y , et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120-123
CrossRef | Web of Science | Medline4
Complete Zometa prescribing information. East Hanover, N.J.: Novartis Pharmaceuticals, November 2004.
- Citing Articles (185)
Citing Articles
1
J. E. O’Connell, O. Ikeagwani, G. J. Kearns. (2012) A role for C-terminal cross-linking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery?. Irish Journal of Medical Science
CrossRef2
Jahan Abtahi, Fredrik Agholme, Olof Sandberg, Per Aspenberg. (2012) Bisphosphonate-induced osteonecrosis of the jaw in a rat model arises first after the bone has become exposed. No primary necrosis in unexposed bone. Journal of Oral Pathology & Medicineno-no
CrossRef3
Trupti Kolur, Sanjiv C. Nair, Balasubramanya Kumar. (2011) Osteonecrosis of Maxilla Secondary to Bisphosphonate Therapy: A Case Report. Journal of Maxillofacial and Oral Surgery
CrossRef4
Ian R. Reid, Jillian Cornish. (2011) Epidemiology and pathogenesis of osteonecrosis of the jaw. Nature Reviews Rheumatology
CrossRef5
Ana Paula de Souza Faloni, Thallita Pereira Queiroz, Raphael Carlos Comelli Lia, Paulo Sérgio Cerri, Rogério Margonar, Alessandra Nara de Souza Rastelli, Elcio Marcantonio. (2011) Accurate Approach in the Treatment of Oral Bisphosphonate–Related Jaw Osteonecrosis. Journal of Craniofacial Surgery1
CrossRef6
F. Saad, J. E. Brown, C. Van Poznak, T. Ibrahim, S. M. Stemmer, A. T. Stopeck, I. J. Diel, S. Takahashi, N. Shore, D. H. Henry, C. H. Barrios, T. Facon, F. Senecal, K. Fizazi, L. Zhou, A. Daniels, P. Carriere, R. Dansey. (2011) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Annals of Oncology
CrossRef7
T. Amrani Raissouni, P. Moya Espinosa, E. Ramos Moreno, M.D. Martínez Del Valle Torres, S. Sanz Viedma, S.J. Ortega Lozano. (2011) Bisphosphonate-Induced Osteonecrosis of the Jaw in a Patient with Metastatic Breast Cancer. Revista Española de Medicina Nuclear (English Edition) 30:5, 322-323
CrossRef8
T. Amrani Raissouni, P. Moya Espinosa, E. Ramos Moreno, M.D. Martínez Del Valle Torres, S. Sanz Viedma, S.J. Ortega Lozano. (2011) Osteonecrosis mandibular por bifosfonatos en paciente con cáncer de mama metastásica. Revista Española de Medicina Nuclear 30:5, 322-323
CrossRef9
James J. Zahrowski. (2011) Optimisation des traitements orthodontiques chez les patients sous biphosphonates. L'Orthodontie Française 82:3, 279-298
CrossRef10
Anke Heidewig Hautmann, Sharon Elad, Anita Lawitschka, Hildegard Greinix, Hartmut Bertz, Joerg Halter, Maura Faraci, Lorenz Christian Hofbauer, Stephanie Lee, Daniel Wolff, Ernst Holler. (2011) Metabolic bone diseases in patients after allogeneic hematopoietic stem cell transplantation: Report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Transplant International 24:9, 867-879
CrossRef11
Juliana Lemound, Andrè Eckardt, Horst Kokemüller, Constantin See, Pit Jacob Voss, Frank Tavassol, Martin Rücker, Majeed Rana, Nils-Claudius Gellrich. (2011) Bisphosphonate-associated osteonecrosis of the mandible: reliable soft tissue reconstruction using a local myofascial flap. Clinical Oral Investigations
CrossRef12
Ourania Nicolatou-Galitis, Erofili Papadopoulou, Triantafyllia Sarri, Polyxeni Boziari, Aikaterini Karayianni, Marie-Christine Kyrtsonis, Panagiotis Repousis, Vassilios Barbounis, Cesar A. Migliorati. (2011) Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 112:2, 195-202
CrossRef13
Tara L Aghaloo, Ben Kang, Eric C Sung, Michael Shoff, Matthew Ronconi, Jack E Gotcher, Olga Bezouglaia, Sarah M Dry, Sotirios Tetradis. (2011) Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. Journal of Bone and Mineral Research 26:8, 1871-1882
CrossRef14
Peter Vestergaard, Kristoffer Schwartz, Lars Rejnmark, Leif Mosekilde, Else Marie Pinholt. (2011) Oral Bisphosphonate Use Increases the Risk for Inflammatory Jaw Disease: A Cohort Study. Journal of Oral and Maxillofacial Surgery
CrossRef15
L.-L. Wei, K. Gellynck, Y.-L. Ng, K. Gulabivala, P. Buxton. (2011) The influence of a bisphosphonate on bone generation determined using a chick-femur model. International Endodontic Journal 44:6, 550-559
CrossRef16
Dan M.J. Milstein, Jérôme A.H. Lindeboom, Can Ince. (2011) The influence of zoledronic acid and cyclophosphamide on microcirculation regeneration in healing oral mucosal flaps. Archives of Oral Biology 56:6, 599-606
CrossRef17
Brian J. Gates, Shyamal Das. (2011) Management of osteoporosis in elderly men. Maturitas 69:2, 113-119
CrossRef18
Morie A. Gertz. (2011) The role of bisphosphonate therapy in the global management of multiple myeloma. Leukemia & Lymphoma 52:5, 736-737
CrossRef19
Johannes K.-H. Meier, Daniel Wolff, Steve Pavletic, Hildegard Greinix, Martin Gosau, Hartmut Bertz, Stefanie J. Lee, Ánita Lawitschka, Sharon Elad. (2011) Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. Clinical Oral Investigations 15:2, 127-139
CrossRef20
A. M. Vandone, M. Donadio, M. Mozzati, M. Ardine, M. A. Polimeni, S. Beatrice, L. Ciuffreda, M. Scoletta. (2011) Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Annals of Oncology
CrossRef21
P. Maurer, T. Sandulescu, M.S. Kriwalsky, A. Rashad, S. Hollstein, I. Stricker, F. Hölzle, M. Kunkel. (2011) Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris. International Journal of Oral and Maxillofacial Surgery 40:3, 285-291
CrossRef22
Bente Thoft Jensen, Pascale Dielenseger, Lawrence Drudge-Coates, Karen Flynn, Susanne Hieronymi, H.A.M (Erik) van Muilekom, Ronny Pieters, Lisbeth Bjerregaard Voss. (2011) Taking the lead – Sharing best practice in intravenous bisphosphonate use in urological cancers. European Journal of Oncology Nursing
CrossRef23
M. R. Allen, S. L. Ruggiero. (2011) Osteonecrosis of the Jaw: Recent Clinical and Preclinical Advances. IBMS BoneKEy 8:3, 141-153
CrossRef24
Serge Cremers, Azeez Farooki. (2011) Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone. Annals of the New York Academy of Sciences 1218:1, 80-87
CrossRef25
Salvatore L. Ruggiero. (2011) Bisphosphonate-related osteonecrosis of the jaw: an overview. Annals of the New York Academy of Sciences 1218:1, 38-46
CrossRef26
Cesar A. Migliorati, Joel B. Epstein, Elliot Abt, James R. Berenson. (2011) Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nature Reviews Endocrinology 7:1, 34-42
CrossRef27
Gelsomina L Borromeo, Caroline Brand, John G Clement, Michael McCullough, Wendy Thomson, Elly Flitzanis, John D Wark. (2011) Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study. BMC Musculoskeletal Disorders 12:1, 71
CrossRef28
James R. Berenson, Ori Yellin, John Crowley, Adel Makary, Donald S. Gravenor, Hank H. Yang, Gargi H. Upadhyaya, Ian W. Flinn, Harry Staszewski, Natasha M. Tiffany, Shamel Sanani, Charles M. Farber, Neil Morganstein, Vanessa Bolejack, Youram Nassir, James D. Hilger, Ashkan Sefaradi, Albert Shamouelian, Regina A. Swift. (2011) Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid. American Journal of Hematology 86:1, 25-30
CrossRef29
Arno Wutzl, Sebastian Pohl, Irene Sulzbacher, Rudolf Seemann, Günter Lauer, Rolf Ewers, Johannes Drach, Clemens Klug. (2011) Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws. Head & Neckn/a-n/a
CrossRef30
Vittorio Fusco, Anastasios Loidoris, Giuseppe Colella, Paolo Vescovi, Giuseppina Campisi. (2010) Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment. The Breast 19:5, 432-433
CrossRef31
Tanja Fehm. (2010) Drug associated osteonecrosis of the jaw. The Breast 19:5, 433-434
CrossRef32
Kenneth E. Fleisher, Garrett Welch, Shailesh Kottal, Ronald G. Craig, Deepak Saxena, Robert S. Glickman. (2010) Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 110:4, 509-516
CrossRef33
Pia López-Jornet, Fabio Camacho-Alonso, Francisco Molina-Miñano, Francisco Gomez-Garcia. (2010) Bisphosphonate-associated osteonecrosis of the jaw. Knowledge and attitudes of dentists and dental students: a preliminary study. Journal of Evaluation in Clinical Practice 16:5, 878-882
CrossRef34
O. Filleul, E. Crompot, S. Saussez. (2010) Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. Journal of Cancer Research and Clinical Oncology 136:8, 1117-1124
CrossRef35
, Cesar Augusto Migliorati, Sook-Bin Woo, Ian Hewson, Andrei Barasch, Linda S. Elting, Fred K. L. Spijkervet, Michael T. Brennan. (2010) A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Supportive Care in Cancer 18:8, 1099-1106
CrossRef36
Toshiyuki Yoneda, Hiroshi Hagino, Toshitsugu Sugimoto, Hiroaki Ohta, Shunji Takahashi, Satoshi Soen, Akira Taguchi, Satoru Toyosawa, Toshihiko Nagata, Masahiro Urade. (2010) Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. Journal of Bone and Mineral Metabolism 28:4, 365-383
CrossRef37
Valentina Guarneri, David Miles, Nicholas Robert, Véronique Diéras, John Glaspy, Ian Smith, Christoph Thomssen, Laura Biganzoli, Tanya Taran, PierFranco Conte. (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Research and Treatment 122:1, 181-188
CrossRef38
Yanming Bi, Yamei Gao, Driss Ehirchiou, Chunzhang Cao, Takashi Kikuiri, Anh Le, Songtao Shi, Li Zhang. (2010) Bisphosphonates Cause Osteonecrosis of the Jaw-Like Disease in Mice. The American Journal of Pathology 177:1, 280-290
CrossRef39
M. Bonomi, R. Nortilli, A. Molino, T. Sava, A. Santo, A. Caldara, G. L. Cetto. (2010) Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis. Medical Oncology 27:2, 224-229
CrossRef40
Sabrina Crépin, Marie-Laure Laroche, Bernard Sarry, Louis Merle. (2010) Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: case report and literature review. European Journal of Clinical Pharmacology 66:6, 547-554
CrossRef41
Akishige Hokugo, Russell Christensen, Evelyn M Chung, Eric C Sung, Alan L Felsenfeld, James W Sayre, Neal Garrett, John S Adams, Ichiro Nishimura. (2010) Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. Journal of Bone and Mineral Research 25:6, 1337-1349
CrossRef42
J. W. Hong, W. Nam, I.-H. Cha, S.-W. Chung, H. S. Choi, K. M. Kim, K. J. Kim, Y. Rhee, S.-K. Lim. (2010) Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia. Osteoporosis International 21:5, 847-853
CrossRef43
Tara L. Aghaloo, Alan L. Felsenfeld, Sotirios Tetradis. (2010) Osteonecrosis of the Jaw in a Patient on Denosumab. Journal of Oral and Maxillofacial Surgery 68:5, 959-963
CrossRef44
Eileen Gentleman, Yann C. Fredholm, Gavin Jell, Nasrin Lotfibakhshaiesh, Matthew D. O'Donnell, Robert G. Hill, Molly M. Stevens. (2010) The effects of strontium-substituted bioactive glasses on osteoblasts and osteoclasts in vitro. Biomaterials 31:14, 3949-3956
CrossRef45
Nathaniel S. Treister, Bernard Friedland, Sook-Bin Woo. (2010) Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 109:5, 753-764
CrossRef46
Nicole B Vogt-Ferrier, Max Hugentobler, Brigitte Uebelhart, Martin Tramèr, Victoria Rollason, Nicole B Vogt-Ferrier. 2010. Interventions for treating osteonecrosis of the jaw bones associated with bisphosphonates. .
CrossRef47
Towy Sorel Lazarovici, Ran Yahalom, Shlomo Taicher, Devorah Schwartz-Arad, Oren Peleg, Noam Yarom. (2010) Bisphosphonate-Related Osteonecrosis of the Jaw Associated With Dental Implants. Journal of Oral and Maxillofacial Surgery 68:4, 790-796
CrossRef48
R.A. Williamson. (2010) Surgical management of bisphosphonate induced osteonecrosis of the jaws. International Journal of Oral and Maxillofacial Surgery 39:3, 251-255
CrossRef49
Pongthorn Narongroeknawin, Maria I. Danila, Lewis G. Humphreys Jr, Andrei Barasch, Jeffrey R. Curtis. (2010) Bisphosphonate-associated osteonecrosis of the jaw,with healing after teriparatide:a review of the literature and a case report. Special Care in Dentistry 30:2, 77-82
CrossRef50
N. Zojer, H. Ludwig. (2010) Supportive Therapie bei multiplem Myelom. Der Onkologe 16:3, 298-308
CrossRef51
Noam Yarom, Towy Sorel Lazarovici, Sharon Elad. (2010) Oral Bisphosphonate-Related Osteonecrosis of the Jaw: Incidence, Clinical Features, Prevention, and Treatment Recommendations. Clinical Reviews in Bone and Mineral Metabolism 8:1, 27-31
CrossRef52
Hengwei Zhang, Robert Recker, Wai-Nang Paul Lee, Gary Guishan Xiao. (2010) Proteomics in bone research. Expert Review of Proteomics 7:1, 103-111
CrossRef53
Jan Rustemeyer, Andreas Bremerich. (2010) Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature. Clinical Oral Investigations 14:1, 59-64
CrossRef54
Sharon Elad, Moshe J. Gomori, Noa Ben-Ami, Silvina Friedlander-Barenboim, Eran Regev, Towy S. Lazarovici, Noam Yarom. (2010) Bisphosphonate-related osteonecrosis of the jaw: clinical correlations with computerized tomography presentation. Clinical Oral Investigations 14:1, 43-50
CrossRef55
Yeo-Gab Kim, Baek-Soo Lee, Yong-Dae Kwon, Joon-Ho Suh, Sang-Mi Jeen. (2010) Study on bisphosphonate-related osteonecrosis of the jaw (BRONJ): case report and literature review. Journal of the Korean Association of Oral and Maxillofacial Surgeons 36:4, 291
CrossRef56
Robert John W. Knight, Chaithan Reddy, Michael A. Rtshiladze, Gregory Lvoff, David Sherring, Damian Marucci. (2010) Bisphosphonate-Related Osteonecrosis of the Jaw. Journal of Craniofacial Surgery 21:1, 25-32
CrossRef57
Corey Langer, Vera Hirsh. (2010) Skeletal morbidity in lung cancer patients with bone metastases: Demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer 67:1, 4-11
CrossRef58
Ali Haidar, Morten Jønler, Troels B. Folkmar, Lars Lund. (2009) Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw. Scandinavian Journal of Urology and Nephrology 43:6, 442-444
CrossRef59
Salvatore L. Ruggiero, Thomas B. Dodson, Leon A. Assael, Regina Landesberg, Robert E. Marx, Bhoomi Mehrotra. (2009) American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaw â 2009 Update. Australian Endodontic Journal 35:3, 119-130
CrossRef60
Brooke S. Crawford, Robert M. McNulty, Eric H. Kraut, Robert C. Turowski. (2009) Extended Use of Intravenous Bisphosphonate Therapy for the Prevention of Skeletal Complications in Patients with Cancer. Cancer Investigation 27:10, 984-988
CrossRef61
Philippe Lesclous, Semaan Abi Najm, Jean-Pierre Carrel, Brigitte Baroukh, Tommaso Lombardi, Jean-Pierre Willi, René Rizzoli, Jean-Louis Saffar, Jacky Samson. (2009) Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation?. Bone 45:5, 843-852
CrossRef62
Jennifer Lee. (2009) Complication Related to Bisphosphonate Therapy. Journal of Infusion Nursing 32:6, 330-335
CrossRef63
Luis Junquera, Lorena Gallego, Paz Cuesta, Alejandro Pelaz, Juan Carlos de Vicente. (2009) Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases. American Journal of Otolaryngology 30:6, 390-395
CrossRef64
S Fedele, N Kumar, R Davies, J Fiske, S Greening, S Porter. (2009) Dental management of patients at risk of osteochemonecrosis of the jaws: a critical review. Oral Diseases 15:8, 527-537
CrossRef65
G. Favia, G.P. Pilolli, E. Maiorano. (2009) Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: An analysis of 31 cases with confocal laser scanning microscopy. Bone 45:3, 406-413
CrossRef66
Carlos Madrid, Mariano Sanz. (2009) What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clinical Oral Implants Research 20, 87-95
CrossRef67
ME Sarasquete, M González, JF San Miguel, R García-Sanz. (2009) Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Diseases 15:6, 382-387
CrossRef68
T. Fehm, D. Felsenberg, M. Krimmel, E. Solomayer, D. Wallwiener, P. Hadjii. (2009) Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: Recommendations for prevention and treatment. The Breast 18:4, 213-217
CrossRef69
E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, M.-A. Dimopoulos, T. Facon, M. Macro, A. Waage, P. Sonneveld. (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Annals of Oncology 20:8, 1303-1317
CrossRef70
Sedat Cetiner, Gulsan Turkoz Sucak, Sevil Altundag Kahraman, Sahika Zeynep Akı, Benay Kocakahyaoglu, Sibel Elif Gultekin, Mustafa Cetiner, Rauf Haznedar. (2009) Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. Journal of Bone and Mineral Metabolism 27:4, 435-443
CrossRef71
Salvatore L. Ruggiero, Thomas B. Dodson, Leon A. Assael, Regina Landesberg, Robert E. Marx, Bhoomi Mehrotra. (2009) American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws—2009 Update. Journal of Oral and Maxillofacial Surgery 67:5, 2-12
CrossRef72
Ghasem Omati Shabestari, Yadollah Soleimani Shayesteh, Arash Khojasteh, Marzieh Alikhasi, Neda Moslemi, Amin Aminian, Reza Masaeli, Behnam Eslami, Nathaniel S. Treister. (2009) Implant Placement in Patients with Oral Bisphosphonate Therapy: A Case Series. Clinical Implant Dentistry and Related Research
CrossRef73
Thomas B. Dodson. (2009) Intravenous Bisphosphonate Therapy and Bisphosphonate-Related Osteonecrosis of the Jaws. Journal of Oral and Maxillofacial Surgery 67:5, 44-52
CrossRef74
Eric R. Carlson, John D. Basile. (2009) The Role of Surgical Resection in the Management of Bisphosphonate-Related Osteonecrosis of the Jaws. Journal of Oral and Maxillofacial Surgery 67:5, 85-95
CrossRef75
M. Dickinson, H. M. Prince, S. Kirsa, A. Zannettino, S. D. J. Gibbs, L. Mileshkin, J. O'Grady, J. F. Seymour, J. Szer, N. Horvath, D. E. Joshua. (2009) Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Internal Medicine Journal 39:5, 304-316
CrossRef76
Sonia B. Gill, Maria P. Valencia, Mary Lou C. Sabino, Gregory M. Heideman, Michelle A. Michel. (2009) Bisphosphonate-Related Osteonecrosis of the Mandible and Maxilla. Journal of Computer Assisted Tomography 33:3, 449-454
CrossRef77
Christian Walter, Bilal Al-Nawas, Andreas du Bois, Laura Buch, Philipp Harter, Knut A. Grötz. (2009) Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 115:8, 1631-1637
CrossRef78
Robin N. Goytia, Andrew Salama, Harpal S. Khanuja. (2009) Bisphosphonates and Osteonecrosis: Potential Treatment or Serious Complication?. Orthopedic Clinics of North America 40:2, 223-234
CrossRef79
Yukako Mouri, Miwa Yoshida, Shogo Nakano, Kyoko Yorozuya, Kimihito Fujii, Takashi Fukutomi, Toshiaki Nakaoka, Shiro Yamada, Kazuo Hara. (2009) A case of osteonecrosis of the jaw in a breast cancer patient with bone metastases receiving long-term treatment with bisphosphonates. Breast Cancer 16:2, 147-150
CrossRef80
Towy Sorel Lazarovici, Ran Yahalom, Shlomo Taicher, Sharon Elad, Izhar Hardan, Noam Yarom. (2009) Bisphosphonate-Related Osteonecrosis of the Jaws: A Single-Center Study of 101 Patients. Journal of Oral and Maxillofacial Surgery 67:4, 850-855
CrossRef81
T. Fehm, V. Beck, M. Banys, H.P. Lipp, M. Hairass, S. Reinert, E.F. Solomayer, D. Wallwiener, M. Krimmel. (2009) Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecologic Oncology 112:3, 605-609
CrossRef82
Hani Mawardi, Nathaniel Treister, Paul Richardson, Kenneth Anderson, Nikhil Munshi, Robert A. Faiella, Sook-Bin Woo. (2009) Sinus Tracts—An Early Sign of Bisphosphonate-Associated Osteonecrosis of the Jaws?. Journal of Oral and Maxillofacial Surgery 67:3, 593-601
CrossRef83
Sven Saussez, Rokneddine Javadian, Chloé Hupin, Michèle Magremanne, Gilbert Chantrain, Isabelle Loeb, Christine Decaestecker. (2009) Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: A belgian case series. The Laryngoscope 119:2, 323-329
CrossRef84
Salvatore L. Ruggiero, Bhoomi Mehrotra. (2009) Bisphosphonate-Related Osteonecrosis of the Jaw: Diagnosis, Prevention, and Management. Annual Review of Medicine 60:1, 85-96
CrossRef85
N Treister, N Sheehy, EH Bae, B Friedland, M Lerman, S Woo. (2009) Dental panoramic radiographic evaluation in bisphosphonate-associated osteonecrosis of the jaws. Oral Diseases 15:1, 88-92
CrossRef86
Kenneth E. Fleisher, Robert S. Glickman. (2009) Bisphosphonate-Related Osteonecrosis of the Jaws: A Case-Control Study of Risk Factors in Breast Cancer Patients. Breast Diseases: A Year Book Quarterly 20:2, 135-138
CrossRef87
Jason Lam, Norma Lynn Pearson, Mirella Giudice, Dina MacLeod. (2009) Bisphosphonate-induced osteonecrosis: Fact or fracture?. Canadian Pharmacists Journal 142:1, 36-40
CrossRef88
Z.-F. Sheng, K. Xu, Y.-L. Ma, J.-H. Liu, R.-C. Dai, Y.-H. Zhang, Y.-B. Jiang, E.-Y. Liao. (2009) Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice. Osteoporosis International 20:1, 151-159
CrossRef89
S. Vincent Rajkumar. (2009) Multiple Myeloma. Current Problems in Cancer 33:1, 7-64
CrossRef90
Ian R. Reid, Tim Cundy. (2009) Osteonecrosis of the jaw. Skeletal Radiology 38:1, 5-9
CrossRef91
Steven Lehrer, André Montazem, Lakshmi Ramanathan, Melissa Pessin-Minsley, John Pfail, Richard G. Stock, Rita Kogan. (2009) Bisphosphonate-Induced Osteonecrosis of the Jaws, Bone Markers, and a Hypothesized Candidate Gene. Journal of Oral and Maxillofacial Surgery 67:1, 159-161
CrossRef92
Ian R. Reid. (2009) Osteonecrosis of the jaw — Who gets it, and why?. Bone 44:1, 4-10
CrossRef93
Brian L. Foster, Kevin A. Tompkins, R. Bruce Rutherford, Hai Zhang, Emily Y. Chu, Hanson Fong, Martha J. Somerman. (2008) Phosphate: Known and potential roles during development and regeneration of teeth and supporting structures. Birth Defects Research Part C: Embryo Today: Reviews 84:4, 281-314
CrossRef94
Kenneth E. Fleisher, Steven Doty, Shailesh Kottal, Joan Phelan, Robert G. Norman, Robert S. Glickman. (2008) Tetracycline-Guided Debridement and Cone Beam Computed Tomography for the Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw: A Technical Note. Journal of Oral and Maxillofacial Surgery 66:12, 2646-2653
CrossRef95
Seth M Arum. (2008) New developments surrounding the safety of bisphosphonates. Current Opinion in Endocrinology, Diabetes and Obesity 15:6, 508-513
CrossRef96
Dora Beke, Martin Pecherstorfer. (2008) Bisphosphonate und Kiefernekrose – eine zunehmende Herausforderung in der Palliativmedizin. Wiener Medizinische Wochenschrift 158:23-24, 702-706
CrossRef97
Nicla La Verde, Claudia Bareggi, Marina Garassino, Karen Borgonovo, Paola Sburlati, Donata Pedretti, Celso Bianchi, Silvia Perrone, Dorian Mihali, Stefano Cobelli, Cristina Mantica, Aurora Rizzo, Gabriella Farina. (2008) Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution. Supportive Care in Cancer 16:11, 1311-1315
CrossRef98
Christian Walter, Bilal Al-Nawas, Knut A. Grötz, Christian Thomas, Joachim W. Thüroff, Viktoria Zinser, Heinold Gamm, Joachim Beck, Wilfried Wagner. (2008) Prevalence and Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaw in Prostate Cancer Patients with Advanced Disease Treated with Zoledronate. European Urology 54:5, 1066-1072
CrossRef99
Brenda Breuer, Marco Pappagallo, Fukiat Ongseng, Chieh-I Chen, Richard Goldfarb. (2008) An Open-label Pilot Trial of Ibandronate for Complex Regional Pain Syndrome. The Clinical Journal of Pain 24:8, 685-689
CrossRef100
Falk Hoffmann, Tatjana I. Jung, Dieter Felsenberg, Gerd Glaeske. (2008) Pattern of intravenous bisphosphonate use in outpatient care in Germany. Pharmacoepidemiology and Drug Safety 17:9, 896-903
CrossRef101
Steven Lehrer, André Montazem, Lakshmi Ramanathan, Melissa Pessin-Minsley, John Pfail, Richard G. Stock, Rita Kogan. (2008) Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 106:3, 389-391
CrossRef102
Thacharot Boonyapakorn, Ingrid Schirmer, Peter A. Reichart, Isrid Sturm, Gero Massenkeil. (2008) Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncology 44:9, 857-869
CrossRef103
Arno Wutzl, Edwin Biedermann, Felix Wanschitz, Rudolf Seemann, Clemens Klug, Arnulf Baumann, Franz Watzinger, Kurt Schicho, Rolf Ewers, Gabriele Millesi. (2008) Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head & Neck 30:9, 1224-1230
CrossRef104
Shahram Aarabi, Lawrence Draper, Barry Grayson, Geoffrey C. Gurtner. (2008) Bisphosphonate-Associated Osteonecrosis of the Jaw: Successful Treatment at 2-Year Follow-Up. Plastic and Reconstructive Surgery 122:2, 57e-59e
CrossRef105
M. A. Dimopoulos, E. Kastritis, C. Bamia, I. Melakopoulos, D. Gika, M. Roussou, M. Migkou, E. Eleftherakis-Papaiakovou, D. Christoulas, E. Terpos, A. Bamias. (2008) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Annals of Oncology 20:1, 117-120
CrossRef106
Sunil J Wimalawansa. (2008) Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opinion on Drug Safety 7:4, 491-512
CrossRef107
Aliya Khan. (2008) Osteonecrosis of the jaw – relationship to bisphosphonate use: commentary and perspective. Aging Health 4:3, 217-219
CrossRef108
Vincenzo Adamo, Nicola Caristi, Marcello Maugeri Saccà, Giuseppa Ferraro, Concetta Arcanà, Roberto Maisano, Daniele Santini, Giuseppe Tonini. (2008) Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients. Expert Opinion on Pharmacotherapy 9:8, 1351-1361
CrossRef109
J. J. Brown, L. Ramalingam, M. R. Zacharin. (2008) Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?. Clinical Endocrinology 68:6, 863-867
CrossRef110
Ana O Hoff, Béla B Toth, Kadri Altundag, Marcella M Johnson, Carla L Warneke, Mimi Hu, Ajay Nooka, Gilbert Sayegh, Valentina Guarneri, Kimberly Desrouleaux, Jeffrey Cui, Andrea Adamus, Robert F Gagel, Gabriel N Hortobagyi. (2008) Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates. Journal of Bone and Mineral Research 23:6, 826-836
CrossRef111
Jesús M. Fernández Gómez, Miguel Álvarez Múgica, Antonio Jalón Monzón, Jorge García Rodríguez. (2008) Efectividad de los bisfosfonatos en el cáncer de próstata avanzado. Medicina Clínica 130:12, 459-462
CrossRef112
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Dodson, Thomas B., Raje, Noopur S., Caruso, Paul A., Rosenberg, Andrew E., . (2008) Case 9-2008. New England Journal of Medicine 358:12, 1283-1291
Full Text113
John Kosteva, Corey Langer. (2008) The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer. Current Opinion in Oncology 20:2, 155-161
CrossRef114
David G. Pendrys, Stuart L. Silverman. (2008) Osteonecrosis of the jaws and bisphosphonates. Current Osteoporosis Reports 6:1, 31-38
CrossRef115
Enikő Udvardy, Pál Redl, Ildikó Márton. (2008) Biszfoszfonát-kezelés során fellépő állcsontnecrosis. Magyar Onkológia 52:1, 81-87
CrossRef116
Mario H. ABU-ID, Patrick H. WARNKE, Joachim GOTTSCHALK, Ingo SPRINGER, Jörg WILTFANG, Yahya ACIL, Paul A.J. RUSSO, Thomas KREUSCH. (2008) “Bis-phossy jaws” – High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. Journal of Cranio-Maxillofacial Surgery 36:2, 95-103
CrossRef117
Nelson B. Watts, Robert D. Marciani. (2008) Osteonecrosis of the Jaw. Southern Medical Journal 101:2, 160-165
CrossRef118
Bao-Thy Grant, Christopher Amenedo, Katherine Freeman, Richard A. Kraut. (2008) Outcomes of Placing Dental Implants in Patients Taking Oral Bisphosphonates: A Review of 115 Cases. Journal of Oral and Maxillofacial Surgery 66:2, 223-230
CrossRef119
Morten A Karsdal, Kim Henriksen, Michel Arnold, Claus Christiansen. (2008) Calcitonin ??? A Drug of the Past or for the Future?. BioDrugs 22:3, 137-144
CrossRef120
J.V. Lobato, A.C. Maurício, J.M. Rodrigues, M.V. Cavaleiro, P.P. Cortez, L. Xavier, C. Botelho, N. Sooraj Hussain, J.D. Santos. (2008) Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate. Journal of Plastic, Reconstructive & Aesthetic Surgery 61:1, 99-106
CrossRef121
Vittorio Montefusco, Francesca Gay, Francesco Spina, Rosalba Miceli, Massimo Maniezzo, Maria Teresa Ambrosini, Lucia Farina, Sheila Piva, Antonio Palumbo, Mario Boccadoro, Paolo Corradini. (2008) Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leukemia & Lymphoma 49:11, 2156-2162
CrossRef122
Marie-Hélène Vieillard, Jean-Michel Maes, Guillaume Penel, Thierry Facon, Leonardo Magro, Jacques Bonneterre, Bernard Cortet. (2008) Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint Bone Spine 75:1, 34-40
CrossRef123
Carlos Santos, Cayetano Alegre. (2008) Osteonecrosis maxilar, bifosfonatos y artritis reumatoide. Medicina Clínica 130:1, 37
CrossRef124
Morie A. Gertz, Sreenivas Koka. (2008) The dilemma of jaw osteonecrosis in patients with multiple myeloma. Leukemia & Lymphoma 49:11, 2037-2039
CrossRef125
Angela Dispenzieri. (2007) Complications of Myeloma Therapy. Hematology/Oncology Clinics of North America 21:6, 1247-1273
CrossRef126
Pamela M. Aubert, Richard J. O’Donnell. (2007) Palliative care in orthopaedic surgical oncology. Surgical Oncology 16:4, 311-330
CrossRef127
Ingo J. Diel, Ignac Fogelman, Bilal Al-Nawas, Bodo Hoffmeister, Cesar Migliorati, Joseph Gligorov, Kalervo Väänänen, Liisa Pylkkänen, Martin Pecherstorfer, Matti S. Aapro. (2007) Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?. Critical Reviews in Oncology/Hematology 64:3, 198-207
CrossRef128
Joan Bladé, Laura Rosiñol. (2007) Complications of Multiple Myeloma. Hematology/Oncology Clinics of North America 21:6, 1231-1246
CrossRef129
R LIU, V WERTH. (2007) What Is New in the Treatment of Steroid-Induced Osteoporosis?. Seminars in Cutaneous Medicine and Surgery 26:4, 203-209
CrossRef130
J. E. Brown, E. V. McCloskey, J. A. Dewar, J. J. Body, D. A. Cameron, A. N. Harnett, M. Ruutu, O. P. Purohit, R. Tähtelä, R. E. Coleman. (2007) The Use of Bone Markers in a 6-Week Study to Assess the Efficacy of Oral Clodronate in Patients with Metastatic Bone Disease. Calcified Tissue International 81:5, 341-351
CrossRef131
Thomas A. Statz, Janet M. Guthmiller, Lewis A. Humbert, Georgia K. Johnson. (2007) Intravenous Bisphosphonate–Associated Osteonecrosis of the Jaw. Journal of Periodontology 78:11, 2203-2208
CrossRef132
Sundeep Khosla, David Burr, Jane Cauley, David W Dempster, Peter R Ebeling, Dieter Felsenberg, Robert F Gagel, Vincente Gilsanz, Theresa Guise, Sreenivas Koka, Laurie K McCauley, Joan McGowan, Marc D McKee, Suresh Mohla, David G Pendrys, Lawrence G Raisz, Salvatore L Ruggiero, David M Shafer, Lillian Shum, Stuart L Silverman, Catherine H Van Poznak, Nelson Watts, Sook-Bin Woo, Elizabeth Shane. (2007) Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research 22:10, 1479-1491
CrossRef133
Jane Collier. (2007) Bone disorders in chronic liver disease. Hepatology 46:4, 1271-1278
CrossRef134
N. Yarom, R. Yahalom, Y. Shoshani, W. Hamed, E. Regev, S. Elad. (2007) Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporosis International 18:10, 1363-1370
CrossRef135
Alessandro Agrillo, Pierpaolo Sassano, Claudio Rinna, Paolo Priore, Giorgio Iannetti. (2007) Ozone Therapy in Extractive Surgery on Patients Treated With Bisphosphonates. Journal of Craniofacial Surgery 18:5, 1068-1070
CrossRef136
M. Pancholi, A. Edwards, S. Langton. (2007) Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour. BDJ 203:2, 87-89
CrossRef137
S.-B. Woo, D. H. Solomon. (2007) Bisphosphonate Therapy for Cancer and Prevalence of Inflammatory Jaw Conditions. JNCI Journal of the National Cancer Institute 99:13, 986-987
CrossRef138
John J. Freiberger, Rebecca Padilla-Burgos, Austin H. Chhoeu, Kevin H. Kraft, Otto Boneta, R.E. Moon, C.A. Piantadosi. (2007) Hyperbaric Oxygen Treatment and Bisphosphonate-Induced Osteonecrosis of the Jaw: A Case Series. Journal of Oral and Maxillofacial Surgery 65:7, 1321-1327
CrossRef139
Estee P. Wang, Leonard B. Kaban, Gordon J. Strewler, Noopur Raje, Maria J. Troulis. (2007) Incidence of Osteonecrosis of the Jaw in Patients With Multiple Myeloma and Breast or Prostate Cancer on Intravenous Bisphosphonate Therapy. Journal of Oral and Maxillofacial Surgery 65:7, 1328-1331
CrossRef140
Tim Van den Wyngaert, Manon T Huizing, Jan B Vermorken. (2007) Osteonecrosis of the jaw related to the use of bisphosphonates. Current Opinion in Oncology 19:4, 315-322
CrossRef141
A Corso, M Varettoni, P Zappasodi, C Klersy, S Mangiacavalli, G Pica, M Lazzarino. (2007) A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21:7, 1545-1548
CrossRef142
G. Lümmen, H. Rübben, T. Schneider, H. Sperling. (2007) Prävention der Osteoporose – wichtig für den Urologen?. Der Urologe 46:6, 651-655
CrossRef143
John K. Brooks, Allen J. Gilson, Arnold J. Sindler, Steven G. Ashman, Kevin G. Schwartz, Nikolaos G. Nikitakis. (2007) Osteonecrosis of the jaws associated with use of risedronate: Report of 2 new cases. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 103:6, 780-786
CrossRef144
O Kanat, A Ozet, S Ataergin, O Kuzhan, F Arpaci, B Ozturk, S Komurcu, M Ozturk. (2007) Bisphosphonate treatment as a cause of jaw osteonecrosis. Oral Diseases 13:3, 346-347
CrossRef145
Ahmad N. Chaudhry, Salvatore L. Ruggiero. (2007) Osteonecrosis and Bisphosphonates in Oral and Maxillofacial Surgery. Oral and Maxillofacial Surgery Clinics of North America 19:2, 199-206
CrossRef146
Lucio Catalano, Silvana Vecchio, Fara Petruzziello, Rosa Fonti, Barbara Salvatore, Carmen Martorelli, Catello Califano, Giuseppe Caparrotti, Sabrina Segreto, Leonardo Pace, Bruno Rotoli. (2007) Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis. Annals of Hematology 86:6, 415-423
CrossRef147
C. Dannemann, K.W. Grätz, M.O. Riener, R.A. Zwahlen. (2007) Jaw osteonecrosis related to bisphosphonate therapy. Bone 40:4, 828-834
CrossRef148
B. G. M. Durie, . (2007) Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus Statement. Mayo Clinic Proceedings 82:4, 516-517
CrossRef149
Rossi Diego, Ornella D’Orto, Davide Pagani, Alessandro Agazzi, Umberto Marzano, Giancarlo Derada Troletti, Walter Fontanella, Lorenzo Pignataro. (2007) Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 103:3, e1-e5
CrossRef150
Keith L. Kirkwood, Joni A. Cirelli, Jill E. Rogers, William V. Giannobile. (2007) Novel host response therapeutic approaches to treat periodontal diseases. Periodontology 2000 43:1, 294-315
CrossRef151
Colin R Dunstan, Dieter Felsenberg, Markus J Seibel. (2007) Therapy Insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nature Clinical Practice Oncology 4:1, 42-55
CrossRef152
Samantha Pozzi, Raffaella Marcheselli, Stefano Sacchi, Luca Baldini, Francesco Angrilli, Elsa Pennese, Giovanni Quarta, Caterina Stelitano, Giuseppe Caparotti, Stefano Luminari, Pellegrino Musto, Donato Natale, Chiara Broglia, Angela Cuoghi, Daniele Dini, Paolo Di Tonno, Giovanna Leonardi, Graziano Pianezze, Vincenzo Pitini, Giuseppe Polimeno, Luisa Ponchio, Luciano Masini, Maurizio Musso, Mauro Spriano, Giuseppe Pollastri, On behalf of the Gruppo Italiano St. (2007) Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leukemia & Lymphoma 48:1, 56-64
CrossRef153
Claude-Laurent Benhamou. (2007) Effects of osteoporosis medications on bone quality. Joint Bone Spine 74:1, 39-47
CrossRef154
Melissa Mortensen, William Lawson, Andre Montazem. (2007) Osteonecrosis of the Jaw Associated With Bisphosphonate Use: Presentation of Seven Cases and Literature Review. The Laryngoscope 117:1, 30-34
CrossRef155
Bernard Bannwarth. (2007) Drug-Induced Musculoskeletal Disorders. Drug Safety 30:1, 27-46
CrossRef156
Kyu Hyun Yang, Jung Hoon Won, Han Kook Yoon, Jong Hyeon Ryu, Kyo Seok Choo, Jae Shin Kim. (2007) High Concentrations of Pamidronate in Bone Weaken the Mechanical Properties of Intact Femora in a Rat Model. Yonsei Medical Journal 48:4, 653
CrossRef157
James A. Eastham. (2007) Bone Health in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. The Journal of Urology 177:1, 17-24
CrossRef158
Michael R. Rickels, Jacqueline M. Junkins-Hopkins, Thomas S. Metkus, Nayyar Iqbal. (2007) Calcific Uremic Arteriolopathy (Calciphylaxis). The Endocrinologist 17:1, 57-62
CrossRef159
Richard J Wenstrup, Katherine A Kacena, Paige Kaplan, Gregory M Pastores, Ainu Prakash-Cheng, Ari Zimran, Thomas N Hangartner. (2007) Effect of Enzyme Replacement Therapy With Imiglucerase on BMD in Type 1 Gaucher Disease. Journal of Bone and Mineral Research 22:1, 119-126
CrossRef160
M. Hugentobler, M. Richter. (2006) Proposition d’un algorithme de prise en charge médico-dentaire pour les patients traités par bisphosphonates. Revue de Stomatologie et de Chirurgie Maxillo-faciale 107:6, 441-444
CrossRef161
L. Ben Slama. (2006) Où allons-nous avec les bisphosphonates ?. Revue de Stomatologie et de Chirurgie Maxillo-faciale 107:6, 413-414
CrossRef162
S. ELAD, N. YAROM, W. HAMED, S. AYALON, R. YAHALOM, E. REGEV. (2006) Osteomylelitis and necrosis of the jaw in patients treated with bisphosphonates: a comparative study focused on multiple myeloma. Clinical and Laboratory Haematology 28:6, 393-398
CrossRef163
Daniele Santini, Maria Elisabetta Fratto, Bruno Vincenzi, Sara Galluzzo, Giuseppe Tonini. (2006) Zoledronic acid in the management of metastatic bone disease. Expert Opinion on Biological Therapy 6:12, 1333-1348
CrossRef164
Pierre D. Delmas. (2006) Reply. Arthritis & Rheumatism 54:11, 3721-3722
CrossRef165
M. Kleerekoper. (2006) Osteoporosis prevention and therapy: preserving and building strength through bone quality. Osteoporosis International 17:12, 1707-1715
CrossRef166
Catherine Van Poznak, Brent B Ward. (2006) Osteonecrosis of the jaw. Current Opinion in Orthopaedics 17:5, 462-468
CrossRef167
José Manuel Calvo-Villas, María Tapia Torres, José Govantes Rodríguez, Elena Carreter de Granda, Francisco Sicilia Guillén. (2006) Osteonecrosis del maxilar en pacientes con mieloma múltiple durante y después del tratamiento con ácido zoledrónico. Medicina Clínica 127:15, 576-579
CrossRef168
Kostas Zervas, Evgenia Verrou, Zisis Teleioudis, Konstantinos Vahtsevanos, Anastasia Banti, Dimitra Mihou, Dimitris Krikelis, Evangelos Terpos. (2006) Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. British Journal of Haematology 134:6, 620-623
CrossRef169
M. Q. Lacy, A. Dispenzieri, M. A. Gertz, P. R. Greipp, K. L. Gollbach, S. R. Hayman, S. Kumar, J. A. Lust, S. V. Rajkumar, S. J. Russell, T. E. Witzig, S. R. Zeldenrust, D. Dingli, P. L. Bergsagel, R. Fonseca, C. B. Reeder, A. K. Stewart, V. Roy, R. J. Dalton, A. B. Carr, D. Kademani, E. E. Keller, C. F. Viozzi, R. A. Kyle. (2006) Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma. Mayo Clinic Proceedings 81:8, 1047-1053
CrossRef170
D. Kademani, S. Koka, M. Q. Lacy, S. V. Rajkumar. (2006) Primary Surgical Therapy for Osteonecrosis of the Jaw Secondary to Bisphosphonate Therapy. Mayo Clinic Proceedings 81:8, 1100-1103
CrossRef171
R LIU, V WERTH. (2006) What Is New in the Treatment of Steroid-Induced Osteoporosis?. Seminars in Cutaneous Medicine and Surgery 25:2, 72-78
CrossRef172
Eunice Y. Pyon. (2006) Once-monthly Ibandronate for postmenopausal Osteoporosis: Review of a new dosing regimen. Clinical Therapeutics 28:4, 475-490
CrossRef173
M. H. Abu-Id, Y. Açil, J. Gottschalk, T. Kreusch. (2006) Bisphosphonatassoziierte Osteonekrose des Kiefers. Mund-, Kiefer- und Gesichtschirurgie 10:2, 73-81
CrossRef174
Adrien Naveau, Bertrand Naveau. (2006) Osteonecrosis of the jaw in patients taking bisphosphonates. Joint Bone Spine 73:1, 7-9
CrossRef175
Johann Ringe. (2006) Zoledronic acid in the treatment of Paget’s disease and other benign bone disorders. Expert Review of Endocrinology & Metabolism 1:1, 15-24
CrossRef176
Catherine Poznak, Cristina Nadal. (2006) Bone integrity and bone metastases in breast cancer. Current Oncology Reports 8:1, 22-28
CrossRef177
Adrien Naveau, Bertrand Naveau. (2006) Ostéonécroses de la mâchoire et bisphosphonates. Revue du Rhumatisme 73:1, 7-9
CrossRef178
Raja S Bobba, Karen Beattie, Bill Parkinson, Dinesh Kumbhare, Jonathan D Adachi. (2006) Tolerability of Different Dosing Regimens of Bisphosphonates for the Treatment of Osteoporosis and Malignant Bone Disease. Drug Safety 29:12, 1133-1152
CrossRef179
Debby Hwang, Hom-Lay Wang. (2006) Medical Contraindications to Implant Therapy: Part I: Absolute Contraindications. Implant Dentistry 15:4, 353-360
CrossRef180
C. Ortega, R. Faggiuolo, R. Vormola, F. Montemurro, D. Nanni, F. Goia, M. Aglietta. (2006) Jaw complications in breast and prostate cancer patients treated with zoledronic acid. Acta Oncologica 45:2, 216-217
CrossRef181
Claire M Shipman, Babatunde O Oyajobi, Gregory R Mundy. (2005) Advances in the management of myeloma bone disease. Expert Opinion on Pharmacotherapy 6:16, 2781-2791
CrossRef182
A. Cheng, A. Mavrokokki, G. Carter, B. Stein, NL Fazzalari, DF Wilson, A N Goss. (2005) The dental implications of bisphosphonates and bone disease. Australian Dental Journal 50:s2, S4-S4
CrossRef183
G. Ficarra, F. Beninati, I. Rubino, A. Vannucchi, G. Longo, P. Tonelli, G. Pini Prato. (2005) Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. Journal of Clinical Periodontology 32:11, 1123-1128
CrossRef184
Harmon Katz. (2005) Endodontic Implications of Bisphosphonate-Associated Osteonecrosis of the Jaws: A Report of Three Cases. Journal of Endodontics 31:11, 831-834
CrossRef185
A SARATHY, S BOURGEOISJR, G GOODELL. (2005) Bisphosphonate-Associated Osteonecrosis of the Jaws and Endodontic Treatment: Two Case Reports. Journal of Endodontics 31:10, 759-763
CrossRef
